GENEVA (Reuters) – The Gavi Vaccine Alliance is in talks with COVID-19 vaccine manufacturers including China’s state-owned Sinopharm to expand the COVAX pipeline and secure doses for distribution, a Gavi spokeswoman told Reuters on Monday in response to a query.
Sinopharm received emergency use listing from the World Health Organization (WHO) last Friday, making it eligible for the COVAX programme and bolstering Beijing’s push for a bigger role in inoculating the world.
(Reporting by Stephanie Nebehay; Editing by Jan Harvey)
